Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNAâs protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilsonâs disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimerâs disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
äŒæ¥ã³ãŒãTELO
äŒç€ŸåTelomir Pharmaceuticals Inc
äžå Žæ¥Feb 09, 2024
æé«çµå¶è²¬ä»»è
ãCEOãAminov (Erez)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 09
æ¬ç€Ÿæåšå°900 West Platt Street, Suite 200
éœåžTAMPA
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·33606
é»è©±çªå·18138642562
ãŠã§ããµã€ãhttps://telomirpharma.com/
äŒæ¥ã³ãŒãTELO
äžå Žæ¥Feb 09, 2024
æé«çµå¶è²¬ä»»è
ãCEOãAminov (Erez)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã